JP7813240B2 - がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法 - Google Patents

がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法

Info

Publication number
JP7813240B2
JP7813240B2 JP2022563944A JP2022563944A JP7813240B2 JP 7813240 B2 JP7813240 B2 JP 7813240B2 JP 2022563944 A JP2022563944 A JP 2022563944A JP 2022563944 A JP2022563944 A JP 2022563944A JP 7813240 B2 JP7813240 B2 JP 7813240B2
Authority
JP
Japan
Prior art keywords
dose
clostridium butyricum
cfu
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022563944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522716A5 (enExample
JP2023522716A (ja
Inventor
リー，ピーター・ピー
パル，スマンタ・クマール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JP2023522716A publication Critical patent/JP2023522716A/ja
Publication of JP2023522716A5 publication Critical patent/JP2023522716A5/ja
Priority to JP2025174464A priority Critical patent/JP2026031928A/ja
Application granted granted Critical
Publication of JP7813240B2 publication Critical patent/JP7813240B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022563944A 2020-04-21 2021-04-20 がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法 Active JP7813240B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025174464A JP2026031928A (ja) 2020-04-21 2025-10-16 がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013141P 2020-04-21 2020-04-21
US63/013,141 2020-04-21
PCT/US2021/028251 WO2021216618A1 (en) 2020-04-21 2021-04-20 Compositions and methods comprising clostridium butyricum for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025174464A Division JP2026031928A (ja) 2020-04-21 2025-10-16 がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法

Publications (3)

Publication Number Publication Date
JP2023522716A JP2023522716A (ja) 2023-05-31
JP2023522716A5 JP2023522716A5 (enExample) 2024-04-30
JP7813240B2 true JP7813240B2 (ja) 2026-02-12

Family

ID=78270016

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022563944A Active JP7813240B2 (ja) 2020-04-21 2021-04-20 がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法
JP2025174464A Pending JP2026031928A (ja) 2020-04-21 2025-10-16 がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025174464A Pending JP2026031928A (ja) 2020-04-21 2025-10-16 がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法

Country Status (8)

Country Link
US (1) US12589123B2 (enExample)
EP (1) EP4138869A4 (enExample)
JP (2) JP7813240B2 (enExample)
KR (1) KR20230004604A (enExample)
CN (1) CN116390737A (enExample)
AU (1) AU2021261290A1 (enExample)
CA (1) CA3180564A1 (enExample)
WO (1) WO2021216618A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240415900A1 (en) * 2021-10-20 2024-12-19 City Of Hope Clostridium butyricum compositions and methods of using the same
CN115671142A (zh) * 2022-11-15 2023-02-03 中山大学附属第六医院 丁酸梭菌在结直肠癌辅助治疗上的应用
CN116650534B (zh) * 2023-03-10 2026-07-28 中南大学 丁酸梭菌及其细菌外囊泡在制备治疗多发性骨髓瘤或复发难治多发性骨髓瘤制剂中的应用
CN121152637A (zh) * 2023-05-23 2025-12-16 日本米雅利桑制药株式会社 癌治疗用组合药物
CN116687979B (zh) * 2023-06-28 2025-06-20 中国人民解放军陆军军医大学 肠道微生物在稳定肠道谷氨酰胺以及在制备治疗癌症的药物中的应用
CN120131715A (zh) * 2025-03-14 2025-06-13 中山大学孙逸仙纪念医院 膀胱灌注丁酸梭菌免疫制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109771445A (zh) 2019-03-20 2019-05-21 青岛东海药业有限公司 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6153219A (ja) 1984-08-23 1986-03-17 Tadashi Arai 抗腫瘍剤
JP2009269836A (ja) 2008-05-01 2009-11-19 Miyarisan Pharmaceutical Co Ltd 大腸癌細胞増殖抑制物質
EP3518946A4 (en) * 2016-09-27 2020-09-09 Board of Regents, The University of Texas System METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
EP3559257A1 (en) 2016-12-22 2019-10-30 Institut Gustave Roussy (IGR) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
WO2019165285A1 (en) * 2018-02-23 2019-08-29 Crestovo Holdings Llc Microbiome related immunotherapies
WO2019178542A1 (en) * 2018-03-16 2019-09-19 Persephone Biome, Inc. Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109771445A (zh) 2019-03-20 2019-05-21 青岛东海药业有限公司 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anti-Cancer Drugs，2019年，Vol. 30, No. 10，pp. 991-997
J. Clin. Oncol.，2020年02月19日，Vo. 38, No. 6 Suppl.，TPS764

Also Published As

Publication number Publication date
JP2026031928A (ja) 2026-02-25
CN116390737A (zh) 2023-07-04
US12589123B2 (en) 2026-03-31
EP4138869A4 (en) 2024-05-15
JP2023522716A (ja) 2023-05-31
US20230149479A1 (en) 2023-05-18
EP4138869A1 (en) 2023-03-01
KR20230004604A (ko) 2023-01-06
AU2021261290A1 (en) 2022-11-03
WO2021216618A1 (en) 2021-10-28
CA3180564A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US12589123B2 (en) Compositions and methods comprising clostridium butyricum for the treatment of cancer
US20250199005A1 (en) Depleting tumor-specific tregs
EP3209692B1 (en) Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
AU2017380257A1 (en) Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 ab-based treatment
US20260015413A1 (en) Compositions and methods for targeting activin signaling to treat cancer
JP7750871B2 (ja) 治療用細菌組成物
CN115698257A (zh) 利用微生物群和代谢物的力量治疗癌症
TW202011989A (zh) 癌症之治療
JP2021534195A (ja) 標的ＴＧＦ−β阻害によるトリプルネガティブ乳がんの処置
WO2025072639A1 (en) Methods of treating cancer resistant to immune checkpoint therapy and compositions useful for the same
Di Modica Gut microbiota and trastuzumab response in HER2-positive breast cancer
EP4711380A1 (en) Ligand-dependent corepressor, (lcor), mutants and fragments thereof, and uses for cancer therapy
TW202602493A (zh) 用於治療癌症的抗ｃｄ３６抗體
WO2026104810A1 (en) Isolated bacteria or culture supernatants thereof for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240418

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260130

R150 Certificate of patent or registration of utility model

Ref document number: 7813240

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150